Table 3.
Laboratory monitoring of included International epidemiologic Databases to Evaluate AIDS (IeDEA) facilities
| Category and variables | West Africa (n = 21) | Southern Africa (n = 19) | East Africa (n = 43) | Central Africa (n = 12a) | South America (n = 7) | Asia (n = 28b) | North America (n = 7c) | Total (n = 137) |
|---|---|---|---|---|---|---|---|---|
| HIV RNA PCR | ||||||||
| On site | 5 (23.8) | 0 (0) | 5 (11.6) | 7 (58.3) | 4 (57.1) | 18 (64.3) | 5 (71.4) | 44 (32.1) |
| Off site | 7 (31.8) | 0 (0) | 23 (53.5) | 0 (0) | 2 (28.6) | 5 (17.9) | 2 (28.6) | 39 (28.5) |
| Test not available | 1 (4.8) | 0 (0) | 10 (23.3) | 5 (41.7) | 0 (0) | 1 (3.6) | 0 (0) | 17 (12.4) |
| Missing | 8 (38.1) | 19 (100) | 5 (11.6) | 0 (0) | 1 (14.3) | 4 (14.3) | 0 (0) | 37 (27.0) |
| Turnaround time (range) | 1–60 | Unknown/missing | 7–60 | 14–30 | 7–60 | 1–60 | 1–10 | 1–60 |
| HIV DNA PCR | ||||||||
| On site | 3 (14.3) | 0 (0) | 7 (16.3) | 3 (25) | 2 (28.6) | 9 (32.1) | 1 (14.3) | 25 (18.2) |
| Off site | 8 (38.1) | 0 (0) | 33 (76.7) | 0 (0) | 2 (28.6) | 8 (28.6) | 1 (14.3) | 52 (37.9) |
| Test not available | 2 (9.5) | 0 (0) | 3 (7) | 7 (58.3) | 0 (0) | 3 (10.7) | 0 (0) | 15 (10.9) |
| Missing | 8 (38.1) | 19 (100) | 0 (0) | 2 (16.7) | 3 (42.9) | 8 (28.6) | 5 (71.4) | 45 (32.8) |
| Turnaround time (range) | 8–30 | Unknown/missing | 7–30 | 30 | 14–60 | 3–60 | 4–10 | 3–60 |
| CD4+ count | ||||||||
| On site | 11 (52.4) | 0 (0) | 17 (39.5) | 9 (75) | 6 (85.7) | 24 (85.7) | 5 (71.4) | 72 (52.6) |
| Off site | 3 (14.3) | 0 (0) | 26 (60.5) | 3 (25) | 1 (14.2) | 4 (14.3) | 2 (28.6) | 39 (28.5) |
| Test not available | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Missing | 7 (33.3) | 19 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 26 (19.0) |
| Turnaround time (range) | 1–100 | Unknown/missing | 1–30 | 1–7 | 1–15 | 1–14 | 1–5 | 1–100 |
| Hemoglobin | ||||||||
| On site | 12 (57.1) | 0 (0) | 38 (88.4) | 12 (100) | 7 (100) | 25 (89.3) | 5 (71.4) | 99 (72.3) |
| Off site | 2 (9.5) | 0 (0) | 4 (9.3) | 0 (0) | 0 (0) | 3 (10.7) | 2 (28.6) | 11 (8.0) |
| Test not available | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Missing | 7 (33.3) | 19 (100) | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 27 (19.7) |
| Turnaround time (range) | 1–100 | Unknown/missing | 1–30 | <1–3 | 1–15 | <1–3 | <1–2 | <1–100 |
| Total lymphocyte count | ||||||||
| On site | 11 (52.4) | 0 (0) | 16 (37.2) | 10 (83.3) | 7 (100) | 24 (85.7) | 4 (57.1) | 72 (52.6) |
| Off site | 3 (14.3) | 0 (0) | 26 (60.5) | 1 (8.3) | 0 (0) | 3 (10.7) | 3 (42.9) | 36 (26.3) |
| Test not available | 0 (0) | 0 (0) | 0 (0) | 1 (8.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Missing | 7 (33.3) | 19 (100) | 1 (2.3) | 0 (0) | 0 (0) | 1 (3.6) | 0 (0) | 28 (20.4) |
| Turnaround time (range) | 1–100 | Unknown/missing | 1–30 | 1–3 | 1–15 | <1–14 | <1–2 | <1–100 |
| ALT/AST | ||||||||
| On site | 11 (52.4) | 0 (0) | 16 (37.2) | 7 (58.3) | 7 (100) | 24 (85.7) | 5 (71.4) | 70 (51.1) |
| Off site | 3 (14.3) | 0 (0) | 26 (60.5) | 2 (16.7) | 0 (0) | 3 (10.7) | 2 (28.6) | 36 (26.3) |
| Test not available | 0 (0) | 0 (0) | 0 (0) | 3 (25.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Missing | 7 (33.3) | 19 (100) | 1 (2.3) | 0 (0) | 0 (0) | 1 (3.6) | 0 (0) | 28 (20.4) |
| Turnaround time (range) | 1–100 | Unknown/missing | 1–30 | 1–3 | 1–15 | <1–2 | 1–2 | <1–100 |
| Cholesterol | ||||||||
| On site | 9 (42.9) | 0 (0) | 6 (14) | 5 (41.7) | 7 (100) | 25 (89.3) | 5 (71.4) | 57 (41.6) |
| Off site | 5 (23.8) | 0 (0) | 32 (74.4) | 4 (33.3) | 0 (0) | 3 (10.7) | 2 (28.6) | 46 (33.6) |
| Test not available | 0 (0) | 0 (0) | 3 (7) | 2 (16.7) | 0 (0) | 0 (0) | 0 (0) | 5 (3.6) |
| Missing | 7 (33.3) | 19 (100) | 2 (4.7) | 1 (8.3) | 0 (0) | 0 (0) | 0 (0) | 29 (21.2) |
| Turnaround time (range) | 1–100 | Unknown/missing | <1–30 | 1–3 | 1–15 | <1–7 | <1–7 | <1–100 |
| Creatinine | ||||||||
| On site | 11 (52.4) | 0 (0) | 15 (34.9) | 8 (66.7) | 7 (100) | 25 (89.3) | 5 (71.4) | 71 (51.8) |
| Off site | 3 (14.3) | 0 (0) | 27 (62.8) | 1 (8.3) | 0 (0) | 3 (10.7) | 2 (28.6) | 36 (26.3) |
| Test not available | 0 (0) | 0 (0) | 0 (0) | 2 (16.7) | 0 (0) | 0 (0) | 0 (0) | 2 (1.5) |
| Missing | 7 (33.3) | 19 (100) | 1 (2.3) | 1 (8.3) | 0 (0) | 0 (0) | 0 (0) | 28 (20.4) |
| Turnaround time (range) | 1–100 | Unknown/missing | 1–30 | 1–3 | 1–15 | <1–3 | <1–1 | <1–100 |
| Lactate | ||||||||
| On site | 7 (33.3) | 0 (0) | 6 (14) | 2 (16.7) | 5 (71.4) | 21 (75) | 5 (71.4) | 46 (33.6) |
| Off site | 2 (9.5) | 0 (0) | 31 (72.1) | 2 (16.7) | 1 (14.3) | 7 (25) | 2 (28.6) | 45 (32.8) |
| Test not available | 3 (14.3) | 0 (0) | 3 (7) | 6 (50) | 0 (0) | 0 (0) | 0 (0) | 12 (8.8) |
| Missing | 9 (42.9) | 19 (100) | 3 (7) | 2 (16.7) | 1 (14.3) | 0 (0) | 0 (0) | 34 (24.8) |
| Turnaround time (range) | <1–21 | Unknown/missing | 1–30 | 1–3 | 1–2 | <1–3 | <1–2 | <1–30 |
The data are presented as n (%). No data were available for the following laboratory tests: serum albumin, INR, alkaline phosphate, triglycerides, high-density lipoprotein, low-density lipoprotein, glucose, platelet count, total white blood count, urine albumin, urine glucose
ALT/AST alanine transaminase/aspartate transaminase, INR international normalized ratio, PCR polymerase chain reaction
aCentral Africa has 15 facilities but no data were available for three facilities
bAsia–Pacific region has 29 facilities but no data were available for one facility
cNorth America has eight facilities but no data were available for one facility